Last reviewed · How we verify
NCT02294032
The Role of B Cells in Kidney Allograft Dysfunction
trial testing Immunosuppressive Agents in Kidney; Complications, Allograft in 180 participants. Completed in 24 April 2023.
24 April 2023
Quick facts
| Lead sponsor | Loma Linda University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 28 August 2014 |
| Primary completion | 24 April 2023 |
| Estimated completion | 24 April 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Immunosuppressive Agents — full drug profile →
Conditions studied
- Kidney; Complications, Allograft — all drugs for Kidney; Complications, Allograft →
- Transplantation Infection — all drugs for Transplantation Infection →
Sponsor
Loma Linda University
Who can join
Adults 2 to 85, any sex, with Kidney; Complications, Allograft or Transplantation Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to understand the role of specific B cells in activating or repressing an anti-allograft immune response after kidney transplantation. In this study, blood will be collected from kidney transplant patients during different timepoints, prior to and after their transplant. Knowledge gained from study findings will be used to develop therapeutic strategies to prevent antibody-mediated rejection, which is a major cause of long-term graft loss in kidney transplant patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02294032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunosuppressive Agents
Trials testing the same drug.
- NCT06310837 — Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis · NA · active not recruiting
- NCT06047171 — Rescue of Nephrons With ALE.F02 (RENAL-F02) · Phase 2 · recruiting
- NCT05863936 — Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis · Phase 3 · unknown
- NCT06121804 — Immunosuppressants to Postoperative Infection and Death · unknown
- NCT04568421 — Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection · completed
Other Loma Linda University trials
Trials by the same sponsor.
- NCT07213843 — Combined Circulatory and Dietary Interventions for Neuropathy · NA · not yet recruiting
- NCT07130812 — Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain. · NA · recruiting
- NCT06673342 — Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake · NA · completed
- NCT06445842 — Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women · NA · recruiting
- NCT07396831 — Necessity of Post-operative Eye Drops · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02294032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loma Linda University
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02294032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing